Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 12/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CCKAR | P32238 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.32 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.32 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.32 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.32 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.32 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.32 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.32 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.32 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21994532 | 1.00 | REN (0.34) | RENCA2CA9LTA4HCCKAR | |
| SCHEMBL21994748 | 0.91 | CA2 (0.35) | RENCA2CA9LTA4H | |
| SCHEMBL21994747 | 0.91 | CA2 (0.35) | RENCA2CA9LTA4H | |
| SCHEMBL30191309 | 0.88 | PTPN1 (0.42) | — | |
| SCHEMBL21994677 | 0.83 | CA2 (0.36) | RENCA2CA9LTA4HCCKAR | |
| SCHEMBL21994680 | 0.83 | CA2 (0.36) | RENCA2CA9LTA4HCCKAR | |
| SCHEMBL21994480 | 0.82 | FDFT1 (0.37) | LTA4H | |
| SCHEMBL21994482 | 0.82 | FDFT1 (0.37) | LTA4H | |
| SCHEMBL21994700 | 0.81 | PTPN1 (0.42) | — | |
| SCHEMBL30191711 | 0.80 | LTA4H (0.32) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020110008-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | REN 14/4885CA2 3021/4885CA9 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.